This randomized controlled trial will evaluate whether preventive e-Counseling (Heart and Stroke Foundation Action Plan, HSF-AP; http://ww2.heartandstroke.ca/hs_bp2.asp?media=bp) improves blood pressure and lifestyle adherence among subjects diagnosed with Stage 1 or 2 hypertension. Primary hypotheses. 1. e-Counseling (vs. Control) will significantly reduce SBP, DBP and pulse pressure (PP) at the 4-, 12-month outcomes, as measured by a validated protocol for automated BP assessment in the clinic23 which we have used in a previous trial.24 2. e-Counseling (vs. Control) will significantly reduce CVD risk, as measured by lipoprotein cholesterol (total, low-density, and total/high-density ratio) and the Framingham 10-year absolute CHD risk index.25 Secondary hypotheses: 1. e-Counseling (vs. Control) will significantly increase adherence to self-management behaviors at the 4- and 12-month outcomes, as measured by objective and validated indices: - mean 7-day step count recorded by accelerometry - dietary sodium ≤ 100 mmol/day measured by 24-hour urinary sodium - smoke-free living measured by salivary cotinine - fruit and vegetable intake ≥ 9 to12 servings/day, dietary fat < 25% and 2-3 dairy servings/day as measured by an NIH/NCI assessment26 that has been validated for Canadian samples.27.28 - physical activity ≥150 minutes/week as measured by validated assessment29 2. Among subjects who are prescribed antihypertensive medications at baseline, e-Counseling (vs. Control) will significantly increase medication adherence as defined by pharmacy refill data and a validated medication compliance index that we have utilized in a previous trial.30 c.) Physical fitness is measured by the 6-minute walk test d.) Autonomic function and baroreceptor sensitivity are measured by ECG and finometer
Individuals with elevated systolic blood pressure (SBP) are at increased risk for cardiovascular disease (CVD; Risk Ratio, RR = 1.47; 95% CI, 1.24-1.74), stroke (RR, 1.42; 95% CI, 1.03-1.93), coronary heart disease (CHD; RR, 1.44; 95% CI, 1.18-1.77), heart failure (HF; RR, 1.60; 95% CI, 1.15-2.22), and CVD mortality (RR, 1.57; 95% CI, 1.24-2.00).1 Hypertension is prevalent among 19 to 21% of Canadian adults 20-79 years of age, and its prevalence rises to 53% among adults 60-79 years of age2, 3, and higher among elderly adults. Hypertension is treated and controlled among only 66% of Canadian adults (SBP < 140, diastolic BP, DBP, < 90 mmHg).2, 3 This is concerning since the risk of cardiovascular mortality among adults 40-69 years of age rises with elevated BP, doubling with each increase of 20 mmHg systolic or 10 mmHg diastolic, from the base index of 115/75 mmHg.
Condition | Hypertension |
---|---|
Treatment | E-counselling, e-info and usual care |
Clinical Study Identifier | NCT01792076 |
Sponsor | University Health Network, Toronto |
Last Modified on | 7 November 2020 |
,
You have contacted , on
Your message has been sent to the study team at ,
You are contacting
Primary Contact
Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.
Learn moreIf you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Learn moreComplete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.
Learn moreEvery year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteer
Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!
No annotations made yet
Congrats! You have your own personal workspace now.